As the global economy mends, the 2021 growth of Osteoarthritis Gene Therapy will have significant change from previous year. According to our (LP Information) latest study, the global Osteoarthritis Gene Therapy market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Osteoarthritis Gene Therapy market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Osteoarthritis Gene Therapy market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Osteoarthritis Gene Therapy market, reaching US$ million by the year 2028. As for the Europe Osteoarthritis Gene Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Osteoarthritis Gene Therapy players cover Flexion, GeneQuine, Novartis, and Smith & Nephew, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Osteoarthritis Gene Therapy market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals and clinics
Assisted living Facilities
Ambulatory Surgical Centers
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Middle East & Africa
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Smith & Nephew